| Stereochemistry | ACHIRAL |
| Molecular Formula | C10H8BrNO |
| Molecular Weight | 238.081 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CC1=CC(Br)=C(O)C2=C1C=CC=N2
InChI
InChIKey=JMOVFFLYGIQXMM-UHFFFAOYSA-N
InChI=1S/C10H8BrNO/c1-6-5-8(11)10(13)9-7(6)3-2-4-12-9/h2-5,13H,1H3
| Molecular Formula | C10H8BrNO |
| Molecular Weight | 238.081 |
| Charge | 0 |
| Count |
MOL RATIO
1 MOL RATIO (average) |
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Tilbroquinol is a 8-hydroxyquinoline compound exerting antiprotozoal
actions. The mechanism of action for 8-hydroxyquinolines remains unknown, although it has been proposed that these compounds chelate metals necessary for multiple enzymatic catalysis reactions, including DNA synthesis. Tilbroquinol in combination with tiliquinol (INTETRIX capsules) is indicated for the treatment of intestinal amebiasis. Some countries (France, Saudi Arabia) have withdrawn from the market products containing tilbroquinol because of the hepatoxicity.
Approval Year
PubMed
Patents
Sample Use Guides
INTETRIX capsules (Tilbroquinol - 200 mg, Tiliquinol laurylsulfate - 50mg, Tiliquinol - 50mg) 2 capsules in the morning and 2 capsules in the evening.
The treatment should not exceed 10 days.
Route of Administration:
Oral
